Literature DB >> 23800952

Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen.

Ian M Bassett1, Shichun Lun, William R Bishai, Haidan Guo, Joanna R Kirman, Mudassar Altaf, Ronan F O'Toole.   

Abstract

Many whole cell screens of chemical libraries currently in use are based on inhibition of bacterial growth. The goal of this study was to develop a chemical library screening model that enabled detection of compounds that are active against drug-tolerant non-growing cultures of Mycobacterium tuberculosis. An in vitro model of low metabolically active mycobacteria was established with 8 and 30 day old cultures of M. smegmatis and M. tuberculosis, respectively. Reduction of resazurin was used as a measure of viability and the assay was applied in screens of chemical libraries for bactericidal compounds. The model provided cells that were phenotypically-resilient to killing by first and second-line clinical drugs including rifampicin. Screening against chemical libraries identified proteasome inhibitors, NSC310551 and NSC321206, and a structurally-related series of thiosemicarbazones, as having potent killing activity towards aged cultures. The inhibitors were confirmed as active against virulent M. tuberculosis strains including multi- and extensively-drug resistant clinical isolates. Our library screen enabled detection of compounds with a potent level of bactericidal activity towards phenotypically drug-tolerant cultures of M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23800952     DOI: 10.1007/s12275-013-3099-4

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  33 in total

Review 1.  Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective.

Authors:  Stephen H Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

3.  Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

Authors:  Claudia Sala; Neeraj Dhar; Ruben C Hartkoorn; Ming Zhang; Young Hwan Ha; Patricia Schneider; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

Review 4.  How can immunology contribute to the control of tuberculosis?

Authors:  S H Kaufmann
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

5.  How dormant is Mycobacterium tuberculosis during latency? A study integrating genomics and molecular epidemiology.

Authors:  Zhenhua Yang; Mariana Rosenthal; Noah A Rosenberg; Sarah Talarico; Lixin Zhang; Carl Marrs; Vibeke Østergaard Thomsen; Troels Lillebaek; Aase B Andersen
Journal:  Infect Genet Evol       Date:  2011-02-18       Impact factor: 3.342

Review 6.  Experimental models used to study human tuberculosis.

Authors:  Ronan O'Toole
Journal:  Adv Appl Microbiol       Date:  2010-02-20       Impact factor: 5.086

7.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling.

Authors:  Joanna C Betts; Pauline T Lukey; Linda C Robb; Ruth A McAdam; Ken Duncan
Journal:  Mol Microbiol       Date:  2002-02       Impact factor: 3.501

8.  Adaptation of Mycobacterium smegmatis to stationary phase.

Authors:  M J Smeulders; J Keer; R A Speight; H D Williams
Journal:  J Bacteriol       Date:  1999-01       Impact factor: 3.490

9.  Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.

Authors:  Anuradha Alahari; Xavier Trivelli; Yann Guérardel; Lynn G Dover; Gurdyal S Besra; James C Sacchettini; Robert C Reynolds; Geoffrey D Coxon; Laurent Kremer
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

10.  Growth kinetics of Mycobacterium tuberculosis measured by quantitative resazurin reduction assay: a tool for fitness studies.

Authors:  Andrea von Groll; Anandi Martin; Françoise Portaels; Pedro Eduardo Almeida da Silva; Juan Carlos Palomino
Journal:  Braz J Microbiol       Date:  2010-06-01       Impact factor: 2.476

View more
  6 in total

1.  Selective Killing of Dormant Mycobacterium tuberculosis by Marine Natural Products.

Authors:  Carolina Rodrigues Felix; Rashmi Gupta; Sandra Geden; Jill Roberts; Priscilla Winder; Shirley A Pomponi; Maria Cristina Diaz; John K Reed; Amy E Wright; Kyle H Rohde
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 2.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

Review 3.  Anti-tuberculosis treatment strategies and drug development: challenges and priorities.

Authors:  Véronique A Dartois; Eric J Rubin
Journal:  Nat Rev Microbiol       Date:  2022-04-27       Impact factor: 78.297

4.  Identification of small molecules targeting homoserine acetyl transferase from Mycobacterium tuberculosis and Staphylococcus aureus.

Authors:  Deepika Chaudhary; Avantika Singh; Mardiana Marzuki; Abhirupa Ghosh; Saqib Kidwai; Tannu Priya Gosain; Kiran Chawla; Sonu Kumar Gupta; Nisheeth Agarwal; Sudipto Saha; Yashwant Kumar; Krishan Gopal Thakur; Amit Singhal; Ramandeep Singh
Journal:  Sci Rep       Date:  2022-08-13       Impact factor: 4.996

5.  Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents.

Authors:  Francesco Russo; Johan Gising; Linda Åkerbladh; Annette K Roos; Agata Naworyta; Sherry L Mowbray; Anders Sokolowski; Ian Henderson; Torey Alling; Mai A Bailey; Megan Files; Tanya Parish; Anders Karlén; Mats Larhed
Journal:  ChemistryOpen       Date:  2015-04-17       Impact factor: 2.911

6.  The use of resazurin as a novel antimicrobial agent against Francisella tularensis.

Authors:  Deanna M Schmitt; Dawn M O'Dee; Brianna N Cowan; James W-M Birch; Leanne K Mazzella; Gerard J Nau; Joseph Horzempa
Journal:  Front Cell Infect Microbiol       Date:  2013-12-06       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.